
HCA Healthcare (HCA) Stock Forecast & Price Target
HCA Healthcare (HCA) Analyst Ratings
Bulls say
HCA Healthcare has demonstrated strong financial growth, as evidenced by a 3Q25 same-facility revenue increase of 9.2%, supported by a 2.4% rise in adjusted admissions. The company has reported notable positive trends in Medicare Advantage volumes and a solid payer mix, contributing to a 7.1% year-over-year increase in inpatient revenue per admission. Additionally, HCA's management has raised its 2025 adjusted EBITDA guidance to $15.25-15.65 billion, with core operational performance playing a significant role in this positive revision.
Bears say
HCA Healthcare's total debt to LTM EBITDA ratio is at 2.9x, indicating a slight improvement but still reflecting elevated leverage concerns within the business. The company is projecting a 5% headwind to its 2026 earnings estimate, combined with a contraction in its enterprise multiple to 8.75x, suggesting cautious sentiment regarding future profitability growth. Additionally, the anticipated growth rate of 3.9% for 2026 falls below HCA's long-term growth outlook, further highlighting the potential for financial struggles amid a challenging economic landscape.
This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.
HCA Healthcare (HCA) Analyst Forecast & Price Prediction
Start investing in HCA Healthcare (HCA)
Order type
Buy in
Order amount
Est. shares
0 shares